Three Strikes for Glybera; AMT Is Likely Out, of Business

LONDON – The European Medicines Agency (EMA) has given a thumbs down to the gene therapy Glybera (alipogene tiparvovec) for the third time after being asked by the European Commission to think again about its refusal in January to recommend approval of the treatment for the inherited disorder lipoprotein lipase deficiency (LPL).